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Higher MSEs found in indirect mapping were mostly pronounced in lower utilities 
(<0.2). Predicted utilities were slightly higher than actual values when population 
average was used for input (0.3–3%). Similar ﬁ ndings were noted in sub-samples. 
CONCLUSIONS: Both methods produced robust results. Compared to direct 
mapping, indirect mapping better represents the EQ-5D’s descriptive information, 
although with higher MSE/MAE. This research provides algorithms for estimating 
EQ-5D item responses and utilities on the basis of pain scores in absence of direct 
utility evidence. Further investigation using out-of-sample predictions is encouraged.
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OBJECTIVES: Measures commonly used in Hepatitis C (HCV) Health-Related 
Quality of Life (HRQL) research were investigated to determine whether they effec-
tively encompass the disease-speciﬁ c experience of HCV. METHODS: Important 
HCV HRQL dimensions were identiﬁ ed via a review of qualitative and quantitative 
literature. Medline and Embase were interrogated for appropriate studies. Quality and 
relevance of HCV HRQL studies were assessed against FDA and EMEA guidelines. 
The review facilitated construction of a conceptual framework of HCV HRQL. The 
framework was compared against HRQL measures used in HCV research, including 
the SF-36, Hepatitis Quality of Life Questionnaire (HQLQ), Chronic Liver Disease 
Questionnaire (CLDQ), Liver Disease Symptom Index (LDSI 2.0), and Hepatitis B 
Quality of Life instrument (HBQOL). RESULTS: Numerous dimensions encompassing 
the HCV HRQL experience were not adequately represented by common measures. 
Absent from the measures were consideration of treatment adherence and management, 
and management of side effects; HIV/HCV co-infection issues; drug addiction; resilience 
and coping; contagiousness and transmission-related issues; illness uncertainty and 
unpredictability; and changes in body image. HCV dimensions needing further attention 
were liver disease severity; psychiatric complications including emotional volatility; 
cognitive impairment during daily activity; sexual dysfunction; the multidimensional 
nature of stigma; and fatigue variability. CONCLUSIONS: The disease-speciﬁ c experi-
ence of HCV is not fully addressed by any single existing measure. An HCV HRQL 
instrument that is sensitive to the identiﬁ ed dimensions and issues would be of con-
siderable beneﬁ t. Such a measure would help health care providers plan individual 
interventions for problematic HRQL domains, as well as improve patient monitoring 
during treatment and clinical research trials, and contribute to determining the value 
and efﬁ cacy of treatment programs. 
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OBJECTIVES: We conducted a systematic review and meta-analysis comparing the 
incidence of contrast-induced nephropathy (CIN) in patients at risk with chronic 
kidney disease (CKD) undergoing computed tomography (CT). METHODS: Random-
ized controlled clinical trials designated to evaluate the nephrotoxicity related to 
iso-osmolar contrast media (IOCM) compared to low-osmolar contrast media 
(LOCM) were searched in the following electronic databases: PubMed/MEDLINE, 
EMBASE, ISI Web of Knowledge and Virtual Health Library (BVS-BIREME), as well 
as abstracts presented at related scientiﬁ c societies meetings. Prior to data extraction, 
deﬁ nitions of nephrotoxicity were established. We applied a random effects model of 
DerSimonian and Laird, with heterogeneity (Q statistic), publication bias (Egger and 
Begg test) and sensitivity analyses. RESULTS: Five studies were included with 716 
randomized patients. When CIN was deﬁ ned as increased serum creatinine (SCr) ≥ 
25%, the relative risk (RR) was 0.71 (CI95% 0.40 to 1.26)—in favor of IOCM—and 
when it was deﬁ ned as SCr ≥ 0.5 mg/dL it showed a RR 1.48 (CI95% 0.37 to 5.87)—
favoring LOCM—in the four studies used this criterion. CONCLUSIONS: In patients 
with CKD undergoing CT there is a similar risk of CIN with the administration of 
any contrast media studied. CIN incidence depends on the chosen criteria and is lower 
with the deﬁ nition of SCr ≥ 0.5 mg/dL at 24–72 h.
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OBJECTIVES: To examine the effects of comorbidities on the hospital readmission 
rate in renal failure (RF) patients on dialysis. METHODS: We used 2005–2007 U.S. 
MarketScan claims database to identify RF patients under 64 years old. RF dialysis 
patients were identiﬁ ed using ICD-9 and CPT codes. RF patients had to be continu-
ously eligible for at least 6 months after the initial dialysis diagnosis date (index dates). 
Comorbidity scores were measured by the Charlson Comorbidity Index (CCI). We 
identiﬁ ed readmission rates to the hospital within 15 days after the index date. 
ANOVA tests and logistic regression were performed to compare outcomes by CCI. 
RESULTS: A total of 6117 patients were diagnosed with RF. Among those who initi-
ated dialysis treatment, 13.9% and 86.1% were treated with peritoneal dialysis and 
hemodialysis, respectively. Over half of all patients were male (55.2%) and the average 
age was 52.4 years. The most frequent comorbid conditions were hypertension 
(69.1%), diabetes (34.5%), congestive heart failure (CHF) (26.3%), and anemia (26.4 
%). Most patients had low (78%, score < = 3) or moderate (12.0%, score 4–5) CCI 
scores. 7.2% of patients had a score of 6–7 and 125 (2.0%) had a score > 8. Older 
patients had signiﬁ cantly more severe CCI scores (P < 0.001). The average age in the 
moderate and severe co-morbidity groups was 51.7 and 57.4 years old, respectively. 
a total of 1.3% of RF dialysis patients were readmitted to the hospital within 15 days. 
Their readmission rates were signiﬁ cantly associated with the CCI score (P < 0.001). 
Patients over age 50 were signiﬁ cantly more likely to readmit to the hospital (P < 
0.001). Those with a higher CCI score were more likely to readmit to the hospital 
within 15 days (moderate group OR. 3.0, P < 0.001, very high group OR 4.04, P < 
0.001). CONCLUSIONS: For patients with RF, the presence of severe comorbid 
physical conditions was signiﬁ cantly associated with hospital readmission within 15 
days.
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OBJECTIVES: To compare OAB patients to non-OAB patients by assessing their 
pre-existing comorbidities prior to their OAB diagnosis or ﬁ rst OAB treatment. 
METHODS: This retrospective cohort study used the General Electric (GE) Centricity 
EMR database. The study subjects were from between January 1, 1996 to March 30, 
2007. The index date for OAB patients was deﬁ ned as the date of their ﬁ rst prescrip-
tion for an antimuscarinic agent or a diagnosis for OAB identiﬁ ed by ICD-9 codes. 
The index date of non-OAB subjects without diagnosis or pharmacy claim was deﬁ ned 
as a year after the ﬁ rst activity date in the EMR. Subjects ≥18 years old were included 
and had 395 days of continuous enrollment before and after the index date. Non-OAB 
subjects were matched to OAB subjects on 1:1 propensity score matching based on 
age, body mass index (BMI) and gender at baseline. Two linear regressions were 
constructed using the outcome variables of the Charlson Comorbidity Index (CCI), 
using ICD-9 codes, and the Chronic Disease Score (CDS), using prescribed drugs, 
respectfully. RESULTS: There were 38,739 OAB subjects [mean age 61.18 (SD:13.26) 
years; 85.67% women] and 38,739 matched non-OAB subjects [mean age 61.17 (SD:
13.24) years; 85.70% women]. Patients with OAB had higher mean CCI and 
CDS than subjects without OAB [(CCI: 1.17 vs. 1.11 (p-value < 0.001); CDS: 
2.95 vs. 1.74 (p-value < 0.001)]. After controlling for other covariates, the linear 
regressions (n = 22,544) showed that OAB patients had higher CCI and CDS than 
subjects without OAB by 0.037 (p-value < 0.001) and by 0.881 (p-value: < 0.001), 
respectively. CONCLUSIONS: This study determined that pre-existing comorbidities 
were more prevalent in OAB patients than in non-OAB patients. These comorbidities 
should to be taken into account when making the decision on the most appropriate 
treatment option for each individual patient.
PUK4
A SYSTEMATIC REVIEW OF IMMUNOSUPPRESSIVE REGIMENS IN 
LOWER IMMUNOLOGICAL RISK RENAL TRANSPLANT RECIPIENTS
Kang MH, Kim HJ, Ko RK, Ko SK
Pﬁ zer Pharmaceuticals Korea Ltd., Seoul, South Korea
OBJECTIVES: In this study, we conducted a systematic review of three immunosup-
pressive regimens in lower risk renal transplantation and compared their efﬁ cacy. 
METHODS: MEDLINE were searched and two independent reviewers assessed 
studies. We limited the search to English, Randomized controlled trial, Human and 
publication between January 1, 1999~May 31, 2010. Studies which were conducted 
with adult renal transplant patients (>18 years) with lower immunological risk were 
included. Sirolimus + steroid regimen with 3 months cyclosporine, and CNI (Calci-
neurin inhibitor: cyclosporine or tacrolimus) regimen with MMF and steroid were 
eligible for inclusion. a total of 434 studies were retrieved from MEDLINE ﬁ rstly. By 
reviewing title, abstracts and full text, 10 studies were eligible for the inclusion ﬁ nally. 
As outcome data, we extracted patient survival and graft survival. RESULTS: There 
was no head-to-head clinical trial which compared the three regimens concurrently. 
But results from 2 studies shows trend of higher patient and graft survival with low 
dose CNI regimen than standard dose cyclosporine. ELITE-Symphony Study illus-
trated patient and graft survival of 96.5% and 89.3% for standard dose cyclosporine, 
98.2% and 93.1% for low dose cyclosporine, 97.2% and 94.2% for low dose tacro-
limus at 1 year. And CAESAR Study showed 97.1% and 92.4% for standard dose 
cyclosporine, 97.8% and 94.5% for low dose cyclosporine at 1 year. 5 reports from 
‘Rapamune Maintenance Regimen Study’ showed outcomes for sirolimus based 
regimen during 5 years. At 1 year, patient and graft survival were 98.1% and 97.2% 
and decreased thereafter. One study of tacrolimus based regimen reported 2-year 
